ABST yields 1.74% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ABST + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ABST + ABBV for your $10,000?
Absolute Software Corporation develops, markets, and provides software services that support the management and security of computing devices, applications, data, and networks for various organizations. The company's Absolute platform offer Absolute Visibility that provides information on device hardware, software, and location; Absolute Control that provide remediation capabilities, such as the ability to remotely freeze devices and delete data; Absolute Resilience, which offer remote scripting, self-healing for critical apps, investigation and recovery services, and sensitive data identification; Absolute Ransomware Response that enables organizations to assess their ransomware preparedness for endpoints, monitors their endpoint cyber hygiene across the entire device fleet and allows for an expedited endpoint recovery; Absolute VPN an enterprise solution; Absolute ZTNA that protects networks and employees with real time risk analysis; and Absolute Insights for Network provides real-time data about device, application, and network performance in a single pane of glass. The company markets its solutions through device original equipment manufacturers, distributors, and value added resellers, as well as directly to healthcare organizations, educational institutions, governmental agencies, and individual consumers. It operates in North America, the United Kingdom, Vietnam, Germany, Australia, Japan, and Latin America. Absolute Software Corporation was incorporated in 1993 and is headquartered in Vancouver, Canada.
Full ABST Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.